Drug Profile


Alternative Names: Cholib; Simvastatin/fenofibrate; Treakol

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Fournier Pharma
  • Developer AbbVie; Fournier Pharma
  • Class Antihyperlipidaemics; Butyric acids; Naphthalenes; Propionates
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 06 Oct 2015 No recent reports of development identified - Phase-III for Hyperlipidaemia in Russia, Mexico and Argentina (PO)
  • 26 May 2015 No recent reports of development identified - Phase-III for Hyperlipidaemia in Ukraine, Australia, New Zealand (PO)
  • 31 Oct 2013 AbbVie completes a phase III trial in Hyperlipidaemia in Argentina, European Union, Mexico and Russia (NCT01674712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top